Guangzhou Industrial Investment Group visits Reforgene
On March 27, Luo Junfu, Party Secretary and Chairman of Guangzhou Industrial Investment Holding Group Co., Ltd. ("Guangzhou Industrial Investment Capital"), led a team to Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene") for research and guidance. The visit focused on the disruptive technology innovation special project of the National Key R&D Program undertaken by Reforgene (the "disruptive technology project"), aiming to gain a comprehensive understanding of the project's progress and promote the deep integration of gene editing technology and the biomedical industry. Huang Junjiu, co-founder and Chief Scientific Advisor of Reforgene, and other core team members warmly received the delegation and gave a detailed report on the company's development achievements.
Huang Junjiu extended a sincere welcome to the delegation led by Luo Junfu and highlighted the progress of the company's disruptive technology project. Since its establishment, Reforgene has always anchored itself on gene editing technology and pushed forward the development of innovative medicines. With strong scientific research capabilities, the company took the lead in undertaking a Guangdong Provincial Key Area R&D Program in 2022. In 2024, Reforgene achieved another success: its "autologous hematopoietic stem cell gene editing therapy for one-time cure of thalassemia" was officially approved under the disruptive technology innovation special project of the National Key R&D Program.
In terms of product development achievements, the beta-thalassemia medicine RM001 has successfully completed Phase I clinical trials, setting multiple firsts, including the first cure of an adult thalassemia patient in China and the first cure of a thalassemia patient who had undergone splenectomy, with clinical data at an internationally leading level. RM004, the world's first gene editing medicine for alpha-thalassemia, successfully cured the world's first patient. Reforgene has thereby become the only innovative drug technology company in the world to achieve cures for both alpha- and beta-thalassemia.
Moreover, the IND application for Reforgene's ophthalmology medicine RM101 for Usher syndrome has been approved by regulators in both China and the United States, making it the first and only gene medicine approved for clinical use in this indication worldwide. In underlying technology innovation, Reforgene also performs outstandingly: the company has built a proprietary portfolio of gene editing technology tools covering CRISPR/Cas12, CRISPR/Cas13, base editing and epigenetic editing, establishing leading core competitiveness, and is one of the few enterprises with gene editing patents and underlying technology development capabilities.
During the visit, the two sides held in-depth and productive exchanges on topics including the biomedical capital market landscape, clinical translation pathways and business strategy. Both sides agreed that, under the current economic situation, the capital market should increase support for innovative enterprises, helping enterprises with outstanding technological attributes and rich achievements participate in global competition and build China's innovative biomedical brand.
Luo Junfu highly praised Reforgene's achievements in drug R&D and technological innovation. She pointed out that Reforgene, as a leading enterprise in the gene editing industry, has highly forward-looking technological innovation and industrial planning. Guangzhou Industrial Investment Capital will actively leverage its strengths to empower Reforgene across multiple dimensions, from resource connection and policy support to financial services, and strongly promote the company's transformation of scientific and technological achievements.
Huang Junjiu expressed gratitude for the leading role Guangzhou Industrial Investment Capital played in the company's most recent financing round, praising the investment team for being professional and pragmatic and providing strong support for the company's development. He said that Reforgene will live up to shareholder expectations, uphold the mission of "Innovation for Life", and strive to become a city and industry calling card for Guangzhou.
Luo Junfu finally emphasized that the combination of Guangzhou Industrial Investment Capital's capital advantages and Reforgene's technological innovation capabilities will produce strong synergy, jointly promoting Guangzhou's accelerated construction of the "12218" modern industrial system, helping Guangzhou's cell and gene and other future industries achieve high-quality development, and building a "global biomedical innovation and industrial development highland".
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.